{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T23:00:51Z","timestamp":1784674851628,"version":"3.55.0"},"reference-count":76,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T00:00:00Z","timestamp":1774483200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T00:00:00Z","timestamp":1774483200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Democritus University of Thrace"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Nucl Med"],"published-print":{"date-parts":[[2026,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The introduction of prostate-specific membrane antigen-ligand positron emission tomography\/computerised tomography (PSMA-ligand PET\/CT) into clinical practice has altered the prevalence of non\u2011metastatic (by conventional imaging) castration-resistant prostate cancer (nmCRPC). We herewith briefly review the biochemical and imaging parameters in nmCRPC and mainly focus on decoding disease localization using PSMA- ligand PET. The effective restaging with more accurate PSMA PET-based disease identification and characterization potentially signifies the entrance of the nmCRPC stage in the twilight zone. Moreover, it seems plausible that the small fraction of the nmCRPC invisible even on PSMA PET may constitute a latent phase of occult growth of the tumor cells. Supposedly, triggering of PSMA overexpression on the PCa cells under androgen deprivation therapy (ADT) through certain anticancer or other therapies such as protein kinase inhibitors (PKIs), dutasteride, or cholesterol-lowering regimes, might further hasten visualisation of micrometastases on PSMA-ligand PET, eventually transforming the nmCRPC stage into a defined, potentially curable target.<\/jats:p>","DOI":"10.1007\/s12149-026-02195-z","type":"journal-article","created":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T11:22:14Z","timestamp":1774524134000},"page":"845-855","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Non-metastatic castration-resistant prostate cancer in the epoch of PSMA-ligand PET\/CT: twilight?"],"prefix":"10.1007","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9928-6971","authenticated-orcid":false,"given":"Pipitsa N.","family":"Valsamaki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgios","family":"Tsakaldimis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,26]]},"reference":[{"key":"2195_CR1","doi-asserted-by":"crossref","unstructured":"Scher HI, Morris MJ, Stadler WM, Higano C, Basch E, Fizazi K, et al. Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3. J Clin Oncology: Official J Am Soc Clin Oncol [Internet]. 2016 Apr;20(12):1402\u201318. [cited 2020 Nov 19];.","DOI":"10.1200\/JCO.2015.64.2702"},{"issue":"4","key":"2195_CR2","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1016\/j.eururo.2016.08.002","volume":"71","author":"P Cornford","year":"2017","unstructured":"Cornford P, Bellmunt J, Bolla M, Briers E, De Santis M, Gross T, et al. EAU-ESTRO- SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer. Eur Urol. 2017;71(4):630\u201342.","journal-title":"Eur Urol"},{"issue":"2","key":"2195_CR3","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1590\/s1677-5538.ibju.2020.0249.1","volume":"5","author":"LO Reis","year":"2021","unstructured":"Reis LO, Saboya L, Sadi MV. National Consensus on Non-metastatic Castration- Resistant Prostate Cancer: more than just a snapshot. Int braz j urol. 2021;5(2):374\u20137.","journal-title":"Int braz j urol"},{"issue":"6","key":"2195_CR4","doi-asserted-by":"publisher","first-page":"S643","DOI":"10.1016\/S1166-7087(22)00174-9","volume":"32","author":"M Baboudjian","year":"2022","unstructured":"Baboudjian M, Gauth\u00e9 M, Barret E, Brureau L, Rocchi P, Cr\u00e9hange G, et al. How PET- CT is Changing the Management of Non-metastatic Castration-resistant Prostate Cancer? Progr\u00e8s en Urologie. 2022;32(6):S643\u201353.","journal-title":"Progr\u00e8s en Urologie"},{"issue":"1","key":"2195_CR5","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1002\/pros.2990020109","volume":"2","author":"MC Wang","year":"1981","unstructured":"Wang MC, Papsidero LD, Kuriyama M, Valenzuela LA, Murphy GP, Chu TM. Prostate antigen: A new potential marker for prostatic cancer. Prostate. 1981;2(1):89\u201396.","journal-title":"Prostate"},{"key":"2195_CR6","doi-asserted-by":"publisher","first-page":"1899","DOI":"10.1172\/JCI112185","volume":"76","author":"H Lilja","year":"1985","unstructured":"Lilja H. A kallikrein-like serine prostease in prostatic fluid cleaves the predominant seminal vesicle protein. J Clin Invest. 1985;76:1899\u2013903.","journal-title":"J Clin Invest"},{"issue":"11","key":"2195_CR7","doi-asserted-by":"publisher","first-page":"3461","DOI":"10.1200\/JCO.1999.17.11.3461","volume":"17","author":"GJ Bubley","year":"1999","unstructured":"Bubley GJ, Carducci MA, Dahut WL, Dawson NA, Daliani DD, Eisenberger MA, et al. Eligibility and Response Guidelines for Phase II Clinical Trials in Androgen- Independent Prostate Cancer: Recommendations From the Prostate-Specific Antigen Working Group. J Clin Oncol. 1999;17(11):3461\u20137.","journal-title":"J Clin Oncol"},{"issue":"7","key":"2195_CR8","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1200\/JCO.2007.12.4487","volume":"26","author":"HI Scher","year":"2008","unstructured":"Scher HI, Halabi S, Tannock I, Morris M, Sternberg CN, Carducci MA, et al. Design and End Points of Clinical Trials for Patients With Progressive Prostate Cancer and Castrate Levels of Testosterone: Recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol. 2008;26(7):1148\u201359.","journal-title":"J Clin Oncol"},{"issue":"21","key":"2195_CR9","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1014618","volume":"364","author":"JS de Bono","year":"2011","unstructured":"de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, et al. Abiraterone and Increased Survival in Metastatic Prostate Cancer. N Engl J Med. 2011;364(21):1995\u20132005.","journal-title":"N Engl J Med"},{"key":"2195_CR10","unstructured":"Israeli RS, Powell CT, Fair WR, Heston WD. Molecular cloning of a complementary DNA encoding a prostate-specific membrane antigen. Cancer research [Internet]. 1993 Autumn;53(2):227\u201330."},{"issue":"6","key":"2195_CR11","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1007\/s00259-013-2374-2","volume":"6","author":"M Eder","year":"2013","unstructured":"Eder M, Eisenhut M, Babich J, Haberkorn U. PSMA as a target for radiolabelled small molecules. Eur J Nucl Med Mol Imaging. 2013;6(6):819\u201323.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"2195_CR12","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/1078-1439(95)00002-Y","volume":"1","author":"GL Wright","year":"1995","unstructured":"Wright GL, Haley C, Beckett ML, Schellhammer PF. Expression of prostate-specific membrane antigen in normal, benign, and malignant prostate tissues. Urologic Oncology: Seminars Original Investigations. 1995;1(1):18\u201328.","journal-title":"Urologic Oncology: Seminars Original Investigations"},{"issue":"1","key":"2195_CR13","first-page":"81","volume":"3","author":"DA Silver","year":"1997","unstructured":"Silver DA, Pellicer I, Fair WR, Heston WD, Cordon-Cardo C. Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin Cancer Res. 1997;3(1):81\u20135.","journal-title":"Clin Cancer Res"},{"issue":"11","key":"2195_CR14","doi-asserted-by":"publisher","first-page":"2256","DOI":"10.1002\/(SICI)1097-0142(19980601)82:11<2256::AID-CNCR22>3.0.CO;2-S","volume":"82","author":"DG Bostwick","year":"1998","unstructured":"Bostwick DG, Pacelli A, Blute M, Roche P, Murphy GP. Prostate specific membrane antigen expression in prostatic intraepithelial neoplasia and adenocarcinoma. Cancer. 1998;82(11):2256\u201361.","journal-title":"Cancer"},{"key":"2195_CR15","doi-asserted-by":"crossref","unstructured":"Mannweiler S, Amersdorfer P, Trajanoski S, Terrett JA, King D, Mehes G. Heterogeneity of Prostate-Specific Membrane Antigen (PSMA) Expression in Prostate Carcinoma with Distant Metastasis. Pathol Oncol Res 2008 18;15(2):167\u201372.","DOI":"10.1007\/s12253-008-9104-2"},{"issue":"17","key":"2195_CR16","doi-asserted-by":"publisher","first-page":"6932","DOI":"10.1158\/0008-5472.CAN-09-1682","volume":"69","author":"S Hillier","year":"2009","unstructured":"Hillier S, Maresca KP, Femia FJ, Marquis J, Foss CA, Nguyen N, et al. Preclinical Evaluation of Novel Glutamate-Urea-Lysine Analogues That Target Prostate-Specific Membrane Antigen as Molecular Imaging Pharmaceuticals for Prostate Cancer. Cancer Res. 2009;69(17):6932\u201340.","journal-title":"Cancer Res"},{"key":"2195_CR17","doi-asserted-by":"crossref","unstructured":"Eder M, Sch\u00e4fer M, Bauder-W\u00fcst U, Hull WE, W\u00e4ngler C, Mier W et al. 68Ga- complex lipophilicity and the targeting property of a urea-based PSMA inhibitor for PET imaging. Bioconjugate Chemistry [Internet]. 2012 Apr 18 [cited 2020 Jun 9];23(4):688\u201397.","DOI":"10.1021\/bc200279b"},{"issue":"5","key":"2195_CR18","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1007\/s00259-022-06089-w","volume":"50","author":"WP Fendler","year":"2023","unstructured":"Fendler WP, Eiber M, Beheshti M, Bomanji J, Calais J, Ceci F, et al. PSMA PET\/CT: joint EANM procedure guideline\/SNMMI procedure standard for prostate cancer imaging 2.0. Eur J Nucl Med Mol Imaging. 2023;50(5):1466\u201386.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"24","key":"2195_CR19","doi-asserted-by":"publisher","first-page":"7448","DOI":"10.1158\/1078-0432.CCR-19-1050","volume":"25","author":"WP Fendler","year":"2019","unstructured":"Fendler WP, Weber M, Iravani A, Hofman MS, Calais J, Czernin J, et al. Prostate-Specific Membrane Antigen Ligand Positron Emission Tomography in Men with Nonmetastatic Castration-Resistant Prostate Cancer. Clin Cancer Res. 2019;25(24):7448\u201354.","journal-title":"Clin Cancer Res"},{"issue":"7","key":"2195_CR20","doi-asserted-by":"publisher","first-page":"1626","DOI":"10.1007\/s00259-021-05245-y","volume":"48","author":"F Ceci","year":"2021","unstructured":"Ceci F, Oprea-Lager DE, Emmett L, Adam JA, Bomanji J, Czernin J, et al. E-PSMA: the EANM standardized reporting guidelines v1.0 for PSMA-PET. Eur J Nucl Med Mol Imaging. 2021;48(7):1626\u201338.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"3","key":"2195_CR21","doi-asserted-by":"publisher","first-page":"469","DOI":"10.2967\/jnumed.117.198119","volume":"59","author":"M Eiber","year":"2018","unstructured":"Eiber M, Herrmann K, Calais J, Hadaschik B, Giesel FL, Hartenbach M, et al. Prostate Cancer Molecular Imaging Standardized Evaluation (PROMISE): Proposed miTNM Classification for the Interpretation of PSMA-Ligand PET\/CT. J Nucl Med. 2018;59(3):469\u201378.","journal-title":"J Nucl Med"},{"issue":"2","key":"2195_CR22","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.eururo.2024.11.025","volume":"87","author":"J Stranne","year":"2025","unstructured":"Stranne J, Henry A, Oprea-Lager DE. Use of Prostate-specific Membrane Antigen Positron Emission Tomography\/Computed Tomography for Nodal Staging in Prostate Cancer and Tailoring of Treatment: A Continuing Conundrum. Eur Urol. 2025;87(2):108\u20139.","journal-title":"Eur Urol"},{"key":"2195_CR23","doi-asserted-by":"crossref","unstructured":"Fourquet A, Aveline C, Cussenot O, Cr\u00e9hange G, Montravers F, Talbot J-N et al. 68Ga-PSMA-11 PET\/CT in restaging castration-resistant nonmetastatic prostate cancer: detection rate, impact on patients\u2019 disease management and adequacy of impact. Sci Rep. 2020;10(1).","DOI":"10.1038\/s41598-020-58975-8"},{"issue":"1","key":"2195_CR24","doi-asserted-by":"publisher","first-page":"4551","DOI":"10.1158\/1078-0432.CCR-20-0587","volume":"26","author":"B Wang","year":"2020","unstructured":"Wang B, Liu C, Yu W, Ji M, Zhang Y, Gan H, et al. A Prospective Trial of 68Ga- PSMA and 18F-FDG PET\/CT in Nonmetastatic Prostate Cancer Patients with an Early PSA Progression During Castration. Clin Cancer Res. 2020;26(1):4551\u20138.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"2195_CR25","doi-asserted-by":"publisher","first-page":"88","DOI":"10.2967\/jnumed.120.245456","volume":"62","author":"M Weber","year":"2021","unstructured":"Weber M, Kurek CE, Barbato F, Eiber M, Maurer T, Nader M, et al. PSMA-Ligand PET for Early Castration-Resistant Prostate Cancer: A Retrospective Single-Center Study. J Nuclear Med. 2021;62(1):88\u201391.","journal-title":"J Nuclear Med"},{"key":"2195_CR26","doi-asserted-by":"crossref","unstructured":"Paschalis A, Sheehan B, Riisnaes R, Rodrigues DN, Gurel B, Bertan C, et al. Prostate- specific Membrane Antigen Heterogeneity and DNA Repair Defects in Prostate Cancer. Eur Urol. 2019 Oct;76(4):469\u201378.","DOI":"10.1016\/j.eururo.2019.06.030"},{"issue":"17","key":"2195_CR27","first-page":"6357","volume":"9","author":"JS Ross","year":"2003","unstructured":"Ross JS, Sheehan CE, Fisher HAG, Kaufman RP, Kaur P, Gray K, et al. Correlation of primary tumor prostate-specific membrane antigen expression with disease recurrence in prostate cancer. PubMed. 2003;9(17):6357\u201362.","journal-title":"PubMed"},{"issue":"3","key":"2195_CR28","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1002\/jcb.10661","volume":"91","author":"A Ghosh","year":"2004","unstructured":"Ghosh A, Heston WDW. Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer. J Cell Biochem. 2004;91(3):528\u201339.","journal-title":"J Cell Biochem"},{"issue":"3","key":"2195_CR29","doi-asserted-by":"publisher","first-page":"e497","DOI":"10.1016\/j.clgc.2016.12.029","volume":"15","author":"FL Giesel","year":"2017","unstructured":"Giesel FL, Kesch C, Yun M, Cardinale J, Haberkorn U, Kopka K, et al. 18F-PSMA- 1007 PET\/CT Detects Micrometastases in a Patient With Biochemically Recurrent Prostate Cancer. Clin Genitourin Cancer. 2017;15(3):e497\u20139.","journal-title":"Clin Genitourin Cancer"},{"issue":"9","key":"2195_CR30","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1016\/S1470-2045(19)30415-2","volume":"20","author":"J Calais","year":"2019","unstructured":"Calais J, Ceci F, Eiber M, Hope TA, Hofman MS, Rischpler C, et al. 18F-fluciclovine PET-CT and 68Ga-PSMA-11 PET-CT in patients with early biochemical recurrence after prostatectomy: a prospective, single-centre, single-arm, comparative imaging trial. Lancet Oncol. 2019;20(9):1286\u201394.","journal-title":"Lancet Oncol"},{"issue":"6","key":"2195_CR31","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1007\/s00259-017-3670-z","volume":"44","author":"WP Fendler","year":"2017","unstructured":"Fendler WP, Eiber M, Beheshti M, Bomanji J, Ceci F, Cho S, et al. 68Ga-PSMA PET\/CT: Joint EANM and SNMMI procedure guideline for prostate cancer imaging: version 1.0. Eur J Nucl Med Mol Imaging. 2017;44(6):1014\u201324.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2195_CR32","unstructured":"Mottet N, Cornford P, Van den Bergh RC, Briers E, De Santis M, Fanti S, Gillessen S, Grummet J, Henry AM, Lam TB, Mason MD. EAU-EANM-ESTRO-ESUR-SIOG. Guidelines on prostate cancer. 2020."},{"issue":"4","key":"2195_CR33","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1200\/JOP.19.00699","volume":"16","author":"EJ Trabulsi","year":"2020","unstructured":"Trabulsi EJ, Rumble RB, Vargas HA. Optimum Imaging Strategies for Advanced Prostate Cancer: ASCO Guideline Summary. JCO Oncol Pract. 2020;16(4):170\u20136.","journal-title":"JCO Oncol Pract"},{"key":"2195_CR34","unstructured":"NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines \u00ae) Prostate Cancer Continue NCCN.org NCCN Guidelines for Patients \u00ae available at www.nccn.org\/patients [Internet]. 2022 Available from: https:\/\/isotopia-global.com\/wp-content\/uploads\/2022\/04\/NCCN-guidlines-prostate-cancer-2022.pdf"},{"issue":"8","key":"2195_CR35","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.2967\/jnumed.115.160382","volume":"25","author":"JJ van Morigi","year":"2015","unstructured":"Morigi JJ, Stricker PD, van Leeuwen PJ, Tang R, Ho B, Nguyen Q, et al. Prospective Comparison of 18F-Fluoromethylcholine Versus 68Ga-PSMA PET\/CT in Prostate Cancer Patients Who Have Rising PSA After Curative Treatment and Are Being Considered for Targeted Therapy. J Nucl Med. 2015;25(8):1185\u201390.","journal-title":"J Nucl Med"},{"issue":"5","key":"2195_CR36","doi-asserted-by":"publisher","first-page":"668","DOI":"10.2967\/jnumed.115.154153","volume":"56","author":"M Eiber","year":"2015","unstructured":"Eiber M, Maurer T, Souvatzoglou M, Beer AJ, Ruffani A, Haller B, et al. Evaluation of Hybrid 68Ga-PSMA Ligand PET\/CT in 248 Patients with Biochemical Recurrence After Radical Prostatectomy. J Nucl Med. 2015;56(5):668\u201374.","journal-title":"J Nucl Med"},{"issue":"6","key":"2195_CR37","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1001\/jamaoncol.2019.0096","volume":"5","author":"WP Fendler","year":"2019","unstructured":"Fendler WP, Calais J, Eiber M, Flavell RR, Mishoe A, Feng FY, et al. Assessment of 68Ga-PSMA-11 PET Accuracy in Localizing Recurrent Prostate Cancer. JAMA Oncol. 2019;5(6):856\u201363.","journal-title":"JAMA Oncol"},{"issue":"1","key":"2195_CR38","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.euo.2021.12.002","volume":"6","author":"L Bianchi","year":"2023","unstructured":"Bianchi L, Castellucci P, Farolfi A, Droghetti M, Artigas C, Leite J, et al. Multicenter External Validation of a Nomogram for Predicting Positive Prostate-specific Membrane Antigen\/Positron Emission Tomography Scan in Patients with Prostate Cancer Recurrence. Eur Urol Oncol. 2023;6(1):41\u20138.","journal-title":"Eur Urol Oncol"},{"key":"2195_CR39","doi-asserted-by":"crossref","unstructured":"Oprea-Lager DE, MacLennan S, Bjartell A, Briganti A, Burger IA, de Jong I et al. European Association of Nuclear Medicine Focus 5: Consensus on Molecular Imaging and Theranostics in Prostate Cancer. European Urology [Internet]. 2023;85.","DOI":"10.1016\/j.eururo.2023.09.003"},{"issue":"3","key":"2195_CR40","doi-asserted-by":"publisher","first-page":"552","DOI":"10.3390\/diagnostics11030552","volume":"11","author":"S Awenat","year":"2021","unstructured":"Awenat S, Piccardo A, Carvoeiras P, Signore G, Giovanella L, Prior JO, et al. Diagnostic Role of 18F-PSMA-1007 PET\/CT in Prostate Cancer Staging: A Systematic Review. Diagnostics. 2021;11(3):552.","journal-title":"Diagnostics"},{"issue":"3","key":"2195_CR41","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1002\/bco2.73","volume":"2","author":"S Aluwini","year":"2021","unstructured":"Aluwini S, Oprea-Lager DE, de Barros H, Mehra N, Stoevelaar H, Derya, Yakar, et al. M1a prostate cancer: Results of a Dutch multidisciplinary consensus meeting. BJUI Compass. 2021;2(3):159\u201368.","journal-title":"BJUI Compass"},{"issue":"2","key":"2195_CR42","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1016\/S0090-4295(96)00184-7","volume":"48","author":"GE Wright","year":"1996","unstructured":"Wright GE, Mayer Grob B, Haley CL, Grossman K, Newhall K, Petrylak DP, et al. Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy. Urology. 1996;48(2):326\u201334.","journal-title":"Urology"},{"issue":"7","key":"2195_CR43","doi-asserted-by":"publisher","first-page":"950","DOI":"10.2967\/jnumed.118.223099","volume":"60","author":"L Emmett","year":"2019","unstructured":"Emmett L, Yin C, Crumbaker M, Hruby G, Kneebone A, Epstein RJ, et al. Rapid Modulation of PSMA Expression by Androgen Deprivation: Serial 68Ga-PSMA-11 PET in Men with Hormone-Sensitive and Castrate-Resistant Prostate Cancer Commencing Androgen Blockade. J Nuclear Med. 2019;60(7):950\u20134.","journal-title":"J Nuclear Med"},{"issue":"1","key":"2195_CR44","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.euo.2018.03.010","volume":"1","author":"R Aggarwal","year":"2018","unstructured":"Aggarwal R, Wei XX, Kim W, Small EJ, Ryan CJ, Carroll PR, et al. Heterogeneous Flare in Prostate-specific Membrane Antigen Positron Emission Tomography Tracer Uptake with Initiation of Androgen Pathway Blockade in Metastatic Prostate Cancer. Eur Urol Oncol. 2018;1(1):78\u201382.","journal-title":"Eur Urol Oncol"},{"issue":"5","key":"2195_CR45","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1016\/j.euf.2021.06.006","volume":"8","author":"B Sheehan","year":"2021","unstructured":"Sheehan B, Guo C, Neeb A, Paschalis A, Sandhu S, de Bono JS. Prostate-specific Membrane Antigen Biology in Lethal Prostate Cancer and its Therapeutic Implications. Eur Urol Focus. 2021;8(5):1157\u201368.","journal-title":"Eur Urol Focus"},{"issue":"8","key":"2195_CR46","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1002\/pros.20361","volume":"66","author":"V Yao","year":"2006","unstructured":"Yao V, Bacich DJ. Prostate specific membrane antigen (PSMA) expression gives prostate cancer cells a growth advantage in a physiologically relevant folate environment in vitro. Prostate. 2006;66(8):867\u201375.","journal-title":"Prostate"},{"issue":"2","key":"2195_CR47","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/j.celrep.2019.03.036","volume":"27","author":"T Nguyen","year":"2019","unstructured":"Nguyen T, Brian J, Kirsch R, Asaka, Nabi K, Quinones A, Tan J, et al. Uncovering the Role of N-Acetyl-Aspartyl-Glutamate as a Glutamate Reservoir in Cancer. Cell Rep. 2019;27(2):491\u2013e5016.","journal-title":"Cell Rep"},{"key":"2195_CR48","doi-asserted-by":"crossref","unstructured":"Wolchok JD, Hoos A, O\u2019Day S, Weber JS, Hamid O, Lebb\u00e9 C et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research [Internet]. 2009 Dec 1 [cited 2020 Oct 1];15(23):7412\u201320. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/19934295\/","DOI":"10.1158\/1078-0432.CCR-09-1624"},{"issue":"4","key":"2195_CR49","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1016\/S0889-8529(18)30247-0","volume":"20","author":"F Labrie","year":"1991","unstructured":"Labrie F. Endocrine Therapy for Prostate Cancer. Endocrinol Metab Clin North Am. 1991;20(4):845\u201372.","journal-title":"Endocrinol Metab Clin North Am"},{"issue":"10","key":"2195_CR50","first-page":"2577","volume":"54","author":"GN Thalmann","year":"1994","unstructured":"Thalmann GN, Anezinis PE, Chang SM, Zhau HE, Kim EE, Hopwood VL, et al. Androgen-independent cancer progression and bone metastasis in the LNCaP model of human prostate cancer. PubMed. 1994;54(10):2577\u201381.","journal-title":"PubMed"},{"issue":"4","key":"2195_CR51","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.eururo.2019.01.049","volume":"77","author":"M Perera","year":"2020","unstructured":"Perera M, Papa N, Roberts M, Williams M, Udovicich C, Vela I, et al. Gallium-68 Prostate-specific Membrane Antigen Positron Emission Tomography in Advanced Prostate Cancer\u2014Updated Diagnostic Utility, Sensitivity, Specificity, and Distribution of Prostate-specific Membrane Antigen-avid Lesions: A Systematic Review and Meta- analysis. Eur Urol. 2020;77(4):403\u201317.","journal-title":"Eur Urol"},{"issue":"12","key":"2195_CR52","doi-asserted-by":"publisher","first-page":"2035","DOI":"10.1007\/s00259-018-4067-3","volume":"45","author":"P Caroli","year":"2018","unstructured":"Caroli P, Sandler I, Matteucci F, De Ugo L, Uccelli, Celli M, et al. 68Ga- PSMA PET\/CT in patients with recurrent prostate cancer after radical treatment: prospective results in 314 patients. Eur J Nucl Med Mol Imaging. 2018;45(12):2035\u201344.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"13","key":"2195_CR53","doi-asserted-by":"publisher","first-page":"3674","DOI":"10.1158\/1078-0432.CCR-20-4573","volume":"27","author":"MJ Morris","year":"2021","unstructured":"Morris MJ, Rowe SP, Gorin MA, Saperstein L, Pouliot F, Josephson D, et al. Diagnostic Performance of 18F-DCFPyL-PET\/CT in Men with Biochemically Recurrent Prostate Cancer: Results from the CONDOR Phase III, Multicenter Study. Clin Cancer Res. 2021;27(13):3674\u201382.","journal-title":"Clin Cancer Res"},{"key":"2195_CR54","doi-asserted-by":"crossref","unstructured":"Chen R, Wang Y, Chen Q et al. Dual-tracer PET\/CT identifies an aggressive PSMA-negative\/FDG-positive phenotype predicting early failure of radical prostatectomy in treatment-naive prostate cancer. Eur J Nucl Med Mol Imaging. 2025.","DOI":"10.1007\/s00259-025-07646-9"},{"issue":"04","key":"2195_CR55","doi-asserted-by":"publisher","first-page":"158","DOI":"10.4236\/oju.2021.114015","volume":"11","author":"J Jhonatan G\u00f3mez Dom\u00ednguez, Martin","year":"2021","unstructured":"Jhonatan G\u00f3mez Dom\u00ednguez, Martin J, Luis J. PET\/CT with 18F-PSMA in Patients with Prostate Cancer, Review of the Initial Experience. Open J Urol. 2021;11(04):158\u201375.","journal-title":"Open J Urol"},{"issue":"12","key":"2195_CR56","first-page":"3536","volume":"106","author":"R Ciappuccini","year":"2021","unstructured":"Ciappuccini R, Saguet-Rysanek V, Giffard F, Licaj I, Dorbeau M, Clarisse B, et al. PSMA Expression in Differentiated Thyroid Cancer: Association with Radioiodine, 18FDG Uptake, and Patient Outcome. J Clin Endocrinol Metabolism. 2021;106(12):3536\u201345.","journal-title":"J Clin Endocrinol Metabolism"},{"issue":"14","key":"2195_CR57","first-page":"339","volume":"14","author":"F Turco","year":"2022","unstructured":"Turco F, Gillessen S, Cathomas R, Buttigliero C, Vogl UM. Treatment Landscape for Patients with Castration-Resistant Prostate Cancer: Patient Selection and Unmet Clinical Needs. Res Rep Urol. 2022;14(14):339\u201350.","journal-title":"Res Rep Urol"},{"key":"2195_CR58","doi-asserted-by":"publisher","unstructured":"Hussain M, Fizazi K, Saad F, Rathenborg P, Shore N, Ferreira U et al. Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate Cancer. New England Journal of Medicine [Internet]. 2018 Jun 28 [cited 2019 Oct 27];378(26):2465\u201374. Available from: https:\/\/www.nejm.org\/doi\/full\/https:\/\/doi.org\/10.1056\/NEJMoa1800536","DOI":"10.1056\/NEJMoa1800536"},{"issue":"15","key":"2195_CR59","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1056\/NEJMoa1715546","volume":"378","author":"MR Smith","year":"2018","unstructured":"Smith MR, Saad F, Chowdhury S, Oudard S, Hadaschik BA, Graff JN, et al. Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer. N Engl J Med. 2018;378(15):1408\u201318.","journal-title":"N Engl J Med"},{"issue":"13","key":"2195_CR60","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1056\/NEJMoa1815671","volume":"380","author":"K Fizazi","year":"2019","unstructured":"Fizazi K, Shore N, Tammela TL, Ulys A, Vjaters E, Polyakov S, et al. Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer. N Engl J Med. 2019;380(13):1235\u201346.","journal-title":"N Engl J Med"},{"issue":"1","key":"2195_CR61","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.eururo.2021.03.004","volume":"80","author":"MS Sadaghiani","year":"2021","unstructured":"Sadaghiani MS, Sheikhbahaei S, Werner RA, Pienta KJ, Pomper MG, Solnes LB, et al. A Systematic Review and Meta-analysis of the Effectiveness and Toxicities of Lutetium-177\u2013labeled Prostate-specific Membrane Antigen\u2013targeted Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer. Eur Urol. 2021;80(1):82\u201394.","journal-title":"Eur Urol"},{"issue":"7","key":"2195_CR62","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1002\/pros.24325","volume":"82","author":"MS Sadaghiani","year":"2022","unstructured":"Sadaghiani MS, Sheikhbahaei S, Werner RA, Pienta KJ, Pomper MG, Gorin MA, et al. 177Lu-PSMA radioligand therapy effectiveness in metastatic castration\u2010resistant prostate cancer: An updated systematic review and meta\u2010analysis. Prostate. 2022;82(7):826\u201335.","journal-title":"Prostate"},{"issue":"13","key":"2195_CR63","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1200\/JCO.21.02440","volume":"40","author":"H Sch\u00f6der","year":"2022","unstructured":"Sch\u00f6der H, Hope TA, Knopp M, Kelly WK, Michalski JM, Lerner SP, et al. Considerations on Integrating Prostate-Specific Membrane Antigen Positron Emission Tomography Imaging Into Clinical Prostate Cancer Trials by National Clinical Trials Network Cooperative Groups. J Clin Oncol. 2022;40(13):1500\u20135.","journal-title":"J Clin Oncol"},{"issue":"4","key":"2195_CR64","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1097\/MNM.0000000000001535","volume":"43","author":"A Nautiyal","year":"2022","unstructured":"Nautiyal A, Jha AK, Mithun S, Rangarajan V. Dosimetry in Lu-177-PSMA-617 prostate-specific membrane antigen targeted radioligand therapy: a systematic review. Nucl Med Commun. 2022;43(4):369\u201377.","journal-title":"Nucl Med Commun"},{"issue":"4","key":"2195_CR65","doi-asserted-by":"publisher","first-page":"663","DOI":"10.3390\/diagnostics11040663","volume":"11","author":"S Han","year":"2021","unstructured":"Han S, Woo S, Kim Y, Lee JL, Wibmer AG, Schoder H, et al. Concordance between Response Assessment Using Prostate-Specific Membrane Antigen PET and Serum Prostate-Specific Antigen Levels after Systemic Treatment in Patients with Metastatic Castration Resistant Prostate Cancer: A Systematic Review and Meta-Analysis. Diagnostics. 2021;11(4):663.","journal-title":"Diagnostics"},{"issue":"5","key":"2195_CR66","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/S1470-2045(24)00135-9","volume":"25","author":"L Emmett","year":"2024","unstructured":"Emmett L, Subramaniam S, Crumbaker M, Nguyen A, Joshua AM, Weickhardt A, et al. [177Lu]Lu-PSMA-617 plus enzalutamide in patients with metastatic castration-resistant prostate cancer (ENZA-p): an open-label, multicentre, randomised, phase 2 trial. Lancet oncology\/Lancet Oncol. 2024;25(5):563\u201371.","journal-title":"Lancet oncology\/Lancet Oncol"},{"key":"2195_CR67","unstructured":"National Library of Medicine. Treatment with Darolutamide +\/- Radiation Therapy for Patients with a Castration Resistant Cancer and Metastases Detected by Functional Imaging (PEACE8) [Internet]. Clinicaltrials.gov. 2025. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06276465"},{"key":"2195_CR68","doi-asserted-by":"crossref","unstructured":"Mukherjee R, McGuinness DH, McCall P, Underwood MA, Seywright M, Orange C et al. Upregulation of MAPK pathway is associated with survival in castrate-resistant prostate cancer. Br J Cancer [Internet]. 2011 Jun 7 [cited 2020 Aug 28];104(12):1920\u20138.","DOI":"10.1038\/bjc.2011.163"},{"issue":"10","key":"2195_CR69","doi-asserted-by":"publisher","first-page":"2580","DOI":"10.1158\/0008-5472.CAN-18-2812","volume":"79","author":"S Li","year":"2019","unstructured":"Li S, Fong K, Gritsina G, Zhang A, Zhao JC, Kim J, et al. Activation of MAPK Signaling by CXCR7 Leads to Enzalutamide Resistance in Prostate Cancer. Cancer Res. 2019;79(10):2580\u201392.","journal-title":"Cancer Res"},{"issue":"2","key":"2195_CR70","doi-asserted-by":"publisher","first-page":"e2119","DOI":"10.1038\/cddis.2016.32","volume":"7","author":"AJ Browne","year":"2016","unstructured":"Browne AJ, G\u00f6bel A, Thiele S, Hofbauer LC, Rauner M, Rachner TD. p38 MAPK regulates the Wnt inhibitor Dickkopf-1 in osteotropic prostate cancer cells. Cell Death Dis. 2016;7(2):e2119\u20139.","journal-title":"Cell Death Dis"},{"key":"2195_CR71","doi-asserted-by":"crossref","unstructured":"Kuzmanov A, Salemi S, Eberli D, Kranzb\u00fchler B. Regulation of prostate-specific membrane antigen (PSMA) expression in prostate cancer cells after treatment with dutasteride and lovastatin. Neoplasia [Internet]. 2024 Nov [cited 2025 May 20];57:101045. Available from: https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC11405815\/","DOI":"10.1016\/j.neo.2024.101045"},{"issue":"3","key":"2195_CR72","doi-asserted-by":"publisher","first-page":"515","DOI":"10.3390\/pharmaceutics14030515","volume":"14","author":"S Bagheri","year":"2022","unstructured":"Bagheri S, Mahdie Rahban F, Bostanian F, Esmaeilzadeh A, Bagherabadi S, Zolghadri, et al. Targeting Protein Kinases and Epigenetic Control as Combinatorial Therapy Options for Advanced Prostate Cancer Treatment. Pharmaceutics. 2022;14(3):515\u20135.","journal-title":"Pharmaceutics"},{"issue":"1","key":"2195_CR73","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1146\/annurev-pharmtox-010617-052954","volume":"58","author":"SP Angus","year":"2018","unstructured":"Angus SP, Zawistowski JS, Johnson GL. Epigenetic Mechanisms Regulating Adaptive Responses to Targeted Kinase Inhibitors in Cancer. Annu Rev Pharmacol Toxicol. 2018;58(1):209\u201329.","journal-title":"Annu Rev Pharmacol Toxicol"},{"issue":"9","key":"2195_CR74","first-page":"2572","volume":"50","author":"F Gelardi","year":"2023","unstructured":"Gelardi F, Briganti A, Pini C, Gaia Ninatti G, Gandaglia, Montorsi F, et al. European guidelines update on PSMA PET\/CT for prostate cancer staging\u2014snap. back Real. 2023;50(9):2572\u20135.","journal-title":"back Real"},{"issue":"25","key":"2195_CR75","doi-asserted-by":"publisher","first-page":"1604","DOI":"10.1056\/NEJM198506203122504","volume":"312","author":"AR Feinstein","year":"1985","unstructured":"Feinstein AR, Sosin DM, Wells CK. The Will Rogers Phenomenon. N Engl J Med. 1985;312(25):1604\u20138.","journal-title":"N Engl J Med"},{"issue":"1","key":"2195_CR76","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.euo.2021.12.005","volume":"6","author":"S Fanti","year":"2023","unstructured":"Fanti S, Lalumera E, Hicks R. Facts and Myths About Stage Migration: Should the Will Rogers Phenomenon Ride off into the Distance? Eur Urol Oncol. 2023;6(1):1\u20133.","journal-title":"Eur Urol Oncol"}],"container-title":["Annals of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12149-026-02195-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12149-026-02195-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12149-026-02195-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T22:01:13Z","timestamp":1784671273000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12149-026-02195-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,26]]},"references-count":76,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["2195"],"URL":"https:\/\/doi.org\/10.1007\/s12149-026-02195-z","relation":{},"ISSN":["0914-7187","1864-6433"],"issn-type":[{"value":"0914-7187","type":"print"},{"value":"1864-6433","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,26]]},"assertion":[{"value":"12 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare they have no financial interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The data are supplied in compliance with the principles of the Declaration of Helsinki and its subsequent amendments. The patient has given informed consent to publishing the data.","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}